Cardiology

Semaglutide 2.4 mg use was linked to lower medical costs and inpatient resource utilization among patients with overweight or obesity and heart failure.

A recent study from Korea has drawn connections between sleep duration and regularity and major adverse cardiovascular events.

Survey reveals persistent misconceptions about blood pressure thresholds, symptoms, and management, with most patients willing to act on clinician advice.

This study suggests a causative role of left bundle branch block (LBBB) in patients’ progression to heart failure.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Darren McGuire, MD, to discuss the results of this groundbreaking trial.

An audio recap of the top 5 stories in healthcare news from the week of 08/10-08/16.

ACHIEVE trial data showed spironolactone 25 mg did not reduce cardiovascular mortality and hospitalization due to heart failure in dialysis patients.

The TITRATE-HF study highlights the importance of early and intensive use of guideline-recommended medical therapy, focusing on dose titration.

Stay updated with the latest healthcare breakthroughs, including FDA news and new guidelines, in this week's essential news roundup.

The updated recommendations encourage both patients and clinicians to take a more proactive approach to preventing or managing hypertension.

Recent research has shown long-lasting freedom of documented AF and atrial tachycardia.

Parent company Response Pharmaceuticals has announced RDX-002’s achievement of its primary endpoint, with more data to come from an ongoing extension.

The 2 organizations released a joint statement on challenging the common view of HF as an inevitability and prioritizing preventive measures.

Over 11,000 bottles have been voluntarily recalled in response to a consumer complaint of a foreign substance inside a tablet, later identified as aluminum.

Despite obesity’s well-known influence on AF recurrence, neither comorbidity has a significant influence on outcomes from early rhythm control therapy.

July delivered 9 impactful advancements across the gamut of disciplines in cardiology.

Hosts offer perspective on the topline results from SURPASS-CVOT and what the cardiovascular data on tirzepatide means for care.

Discover the evolving landscape of hypertriglyceridemia treatment, focusing on innovative therapies and improved diagnostic strategies for FCS and MCS.

This FDA News Month in Review provides a round-up of regulatory decisions from July 2025.

Panelists discuss differentiators between nsMRA and steroidal MRAs in the context of heart failure.

Panelists offer perspective on the role of finerenone in combination therapy approaches in patients with HFmrEF/HFpEF.

Finerenone's FDA approval marks a transformative step in heart failure treatment, offering early benefits and broad applicability.

Finerenone's FDA approval marks a breakthrough in heart failure treatment, significantly reducing cardiovascular events and hospitalizations for patients.

Inclisiran can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in hypercholesterolemia.

Tirzepatide was non-inferior to dulaglutide with an 8% lower rate of MACE-3 events while delivering greater reductions in A1C and weight.